Examining the impact of COVID-19 disruptions on population-based breast cancer screening in Ireland
Journal of Medical Screening · 2024
DOI: 10.1177/09691413241232899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, 2024. Verfasst von Jessica O'Driscoll und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: COVID-19, Breast Neoplasms, Mammography, Early Detection of Cancer. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Health Research Board of Ireland.
Abstract (Originalsprache)
Objective
Many population-based breast screening programmes temporarily suspended routine screening following the COVID-19 pandemic onset. This study aimed to describe screening mammography utilisation and the pattern of screen-detected breast cancer diagnoses following COVID-19-related screening disruptions in Ireland.
Methods
Using anonymous aggregate data from women invited for routine screening, three time periods were examined: (1) January–December 2019, (2) January–December 2020, and (3) January–December 2021. Descriptive statistics were conducted and comparisons between groups were performed using chi-square tests.
Results
In 2020, screening mammography capacity fell by 67.1% compared to 2019; recovering to 75% of mammograms performed in 2019, during 2021. Compared to 2019, for screen-detected invasive breast cancers, a reduction in Grade 1 (14.2% vs. 17.2%) and Grade 2 tumours (53.4% vs. 58.0%) and an increase in Grade 3 tumours (32.4% vs. 24.8%) was observed in 2020 ( p = 0.03); whereas an increase in Grade 2 tumours (63.3% vs. 58.0%) and a reduction in Grade 3 tumours (19.6% vs. 24.8%) was found in 2021 ( p = 0.02). No changes in oestrogen receptor-positive or nodal-positive diagnoses were observed; however the proportion of oestrogen/progesterone receptor-positive breast cancers significantly increased in 2020 (76.2%; p < 0.01) and 2021 (78.7%; p < 0.001) compared to 2019 (67.8%).
Conclusion
These findings demonstrate signs of a grade change for screen-detected invasive breast cancers early in the pandemic, with recovery evident in 2021, and without an increase in nodal positivity. Future studies are needed to determine the COVID-19 impact on long-term breast cancer outcomes including mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- National Screening Service, Dublin, Ireland.
- Health Service Executive, Dublin, Ireland.
- BreastCheck, National Screening Service, Ireland.
- School of Public Health, Physiotherapy & Sports Science, University College Dublin, Ireland.
ORCID-Profile: Jessica O'Driscoll
Förderung
- The Health Research Board of Ireland
Zitieren
APA
O'Driscoll, J., Mooney, T., Kearney, P., Williams, Y., Lynch, S., Connors, A., Larke, A., McNally, S., O'Doherty, A., Murphy, L., Bennett, K. E., Fitzpatrick, P., Mullooly, M., & Flanagan, F. (2024). Examining the impact of COVID-19 disruptions on population-based breast cancer screening in Ireland. Journal of Medical Screening. https://doi.org/10.1177/09691413241232899
Vancouver
O'Driscoll J, Mooney T, Kearney P, Williams Y, Lynch S, Connors A, et al. Examining the impact of COVID-19 disruptions on population-based breast cancer screening in Ireland. Journal of Medical Screening. 2024. doi:10.1177/09691413241232899
BibTeX
@article{ODriscoll2024,
author = {O'Driscoll, Jessica and Mooney, Therese and Kearney, Paul and Williams, Yvonne and Lynch, Suzanne and Connors, Alissa and Larke, Aideen and McNally, Sorcha and O'Doherty, Ann and Murphy, Laura and Bennett, Kathleen E and Fitzpatrick, Patricia and Mullooly, Maeve and Flanagan, Fidelma},
title = {Examining the impact of COVID-19 disruptions on population-based breast cancer screening in Ireland},
journal = {Journal of Medical Screening},
year = {2024},
doi = {10.1177/09691413241232899}
}
EUVIMED